Ipsen

Ipsen S.A. is a French multinational pharmaceutical company that develops, manufactures and markets specialty medicines. Headquartered in Boulogne-Billancourt, near Paris, Ipsen focuses its business on three core therapeutic areas: oncology, neuroscience, and rare diseases, including neuroendocrine disorders. The company operates globally and is listed on Euronext Paris.

Ipsen's product portfolio includes Dysport (abobotulinumtoxinA), a botulinum toxin used in neuromuscular disorders and cosmetic applications; Somatuline (lanreotide) for acromegaly and certain neuroendocrine tumors; and Cabometyx (cabozantinib), an oncology therapy marketed in collaboration with Exelixis in multiple regions. The portfolio also encompasses medicines for other rare diseases and supportive therapies, with a continuing emphasis on developing treatments that address high unmet medical need.

Ipsen emphasizes research and development to advance its pipeline through internal programs and external collaborations. The company maintains manufacturing and distribution capabilities to support its global operations and works with partners and health authorities to bring therapies to patients in Europe, the Americas, and Asia-Pacific. Ipsen also engages in licensing and strategic partnerships to extend its reach in its chosen markets.

Through governance and corporate social responsibility programs, Ipsen aims to balance commercial performance with patient access and sustainable practices. The company competes in the global specialty pharmaceutical sector and seeks to expand its footprint in oncology, neuroscience, and rare diseases.